Last reviewed · How we verify
Non-Biologic DMARDs
Non-biologic DMARDs are small-molecule drugs that suppress the immune system to reduce inflammation and slow disease progression in rheumatoid arthritis and other autoimmune conditions.
Non-biologic DMARDs are small-molecule drugs that suppress the immune system to reduce inflammation and slow disease progression in rheumatoid arthritis and other autoimmune conditions. Used for Rheumatoid arthritis, Other autoimmune inflammatory conditions.
At a glance
| Generic name | Non-Biologic DMARDs |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Drug class | Non-biologic DMARD (conventional synthetic DMARD) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology |
| Phase | Phase 3 |
Mechanism of action
Non-biologic disease-modifying antirheumatic drugs (DMARDs) include conventional synthetic agents such as methotrexate, sulfasalazine, and leflunomide that work through various immunosuppressive pathways to inhibit T-cell proliferation, reduce cytokine production, and modulate immune responses. These agents target intracellular signaling pathways and metabolic processes critical to immune cell activation, thereby reducing joint inflammation and preventing structural damage in rheumatoid arthritis and related autoimmune diseases.
Approved indications
- Rheumatoid arthritis
- Other autoimmune inflammatory conditions
Common side effects
- Hepatotoxicity
- Myelosuppression
- Gastrointestinal disturbances
- Infection risk
- Nausea
Key clinical trials
- A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines (PHASE3)
- Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis (PHASE2)
- A Study of Clinical and Immune Responses to Sequential Biologic Therapies in Psoriatic Arthritis
- Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis
- Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial (PHASE4)
- The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd) (PHASE4)
- RA-PRO PRAGMATIC TRIAL (PHASE3)
- AScalate: Treat-to-target in Axial Spondyloarthritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |